Propanc Biopharma, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2020, with fiscal 2019 comparisons. Although the request identifies “2019 Q4,” this filing reports the full fiscal year ended June 30, 2020, not a standalone quarterly period. Filed October 1, 2020.
Business context
Propanc is a pre-revenue development-stage biotechnology company developing PRP, an intravenous formulation of trypsinogen and chymotrypsinogen, for cancer treatment. PRP remained in preclinical development; the company had not begun human clinical trials or generated product revenue. The company also pursued POP1 research into potential backup compounds.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $3.49 million | $2.61 million |
| Research and development expense | $179,987 | $260,335 |
| Net loss | $4.74 million | $5.76 million |
| Net loss per share | $0.19 | $10.97 |
| Net cash used in operations | $1.85 million | $2.06 million |
| Cash at year-end | $67,007 | $2,394 |
There were no revenues or meaningful operating margins. FY2020 net loss improved by about $1.02 million, while operating expenses rose, principally due to higher stock-based service costs and other administrative expenses. The smaller net loss also reflected a favorable change in derivative fair value compared with FY2019; interest expense increased to $1.75 million from $1.31 million.
Total assets were $98,518 and total current liabilities were $3.74 million at June 30, 2020. Working capital deficit was $3.67 million; stockholders’ deficit was $3.64 million and accumulated deficit was $55.78 million. Balance-sheet convertible notes, accrued interest and premiums, net of discounts, were $1.56 million; the filing separately describes approximately $1.1 million of convertible-note debt and interest, excluding redemption premium. These debt measures are not directly equivalent.
Financing provided $1.89 million of cash in FY2020, including $1.59 million from convertible notes and $450,000 from an equity transaction, net of fees. The company issued approximately 247.6 million shares on conversion of debt during the year. As of June 30, 2020, it reported 151.2 million warrants outstanding and notes convertible into approximately 439.1 million shares.
Changes, outlook and risks
- FY2020 net loss narrowed from FY2019, but administration expense increased to $3.28 million from $2.33 million, while R&D expense declined.
- Management planned a Phase Ib first-in-human study in advanced solid tumors, with at least 20 and up to 40 patients, subject to financing and regulatory approval. The filing gives differing target dates for the clinical-trial application and study start, generally describing submission in 2021 and trial initiation in the second half of 2021. Estimated Phase Ib costs were approximately $6.5 million. Management anticipated later Phase IIa studies and estimated a three-to-four-year path to a proof-of-concept milestone; these are plans, not assured outcomes.
- Management said it lacked sufficient cash to meet obligations over the next 12 months and would need additional debt or equity financing. The auditor’s report and management disclosure raise substantial doubt about the company’s ability to continue as a going concern. The statements include no adjustments for the outcome of that uncertainty.
- Financing risk is amplified by convertible notes with discounted or variable-price conversion terms, potential default premiums, and substantial dilution. The company reported 735.7 million shares reserved for lender conversions at year-end; separate disclosures report 739.1 million shares reserved, a difference to verify.
- Material weaknesses in financial reporting controls remained: no written control procedures, inadequate segregation of duties, no audit committee, and insufficient review and U.S. GAAP expertise. Management said remediation depends partly on obtaining capital.
- Other key risks include clinical and regulatory failure, reliance on third-party manufacturers and researchers, COVID-19-related disruption, uncertain patent protection, and limited staffing. The manufacturing agreement with Amatsigroup expired in 2019 and a written extension was under consideration.
- Litigation includes a former law firm’s claim for approximately $151,000 plus interest and costs, and Regal Consulting’s claims for approximately $400,000, 60,000 shares and additional note-related amounts. The company disputes both claims. It also disclosed accrued IRS penalties of $30,000 plus interest for late historical filings.
- The company received FDA orphan-drug designation for PRP for pancreatic cancer; its ovarian-cancer designation request was denied. Reported preclinical findings are not clinical evidence of safety or effectiveness.
Most important facts for investors to verify
- Whether the company obtained enough financing after the filing to fund operations and the planned clinical program, and whether its going-concern status changed.
- Current note balances, maturity/default status, conversion terms, share reserves, warrant exercises and fully diluted share count; the filing reports substantial dilution and contains differing share-reserve figures.
- Actual regulatory submissions, approvals, trial-site selection, manufacturing readiness and costs versus the stated 2021 plans and $6.5 million estimate.
- Resolution or subsequent developments in the Foley Shechter and Regal disputes, and the status of the related IRS liability.
- Whether the company remediated its material weaknesses and established independent board oversight and an audit committee.
- Share-count and trading-market disclosures: the filing reports 688,670,618 shares outstanding on its cover as of September 28, 2020, while another disclosure gives 668,670,618 as the basis for ownership percentages. Verify the correct figure and subsequent issuances.